VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | BCMA-targeting therapies in myeloma

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, highlights B-cell maturation antigen (BCMA) targeting therapies in multiple myeloma including belantamab mafodotin, a BCMA targeting antibody-drug conjugate, as well as bb2121 and JNJ-68284528, two different BCMA CAR-T cell therapies. Dr Popat also highlights novel BiTEs presented at EHA 2020 such as teclistamab, a BCMA x CD3 bispecific antibody investigated in a Phase I dose-escalation study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter